相关实验视频

Updated: Jul 19, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

基于免疫细胞死亡的预后模型,用于预测肺腺癌的免疫疗法和常见疗法的反应

Xiang Zhou¹, Ran Xu¹, Tong Lu¹

¹Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.

Scientific reports

|August 16, 2023

概括

这项研究确定了与肺腺癌 (LUAD) 免疫细胞死亡 (ICD) 相关的生物标志物. 一个新的预后模型预测了患者对免疫治疗的反应,帮助个性化治疗策略.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学遗传学是一个

背景情况:

肺腺癌 (LUAD) 治疗疗效不同,需要个性化方法.
癌症免疫疗法对LUAD有希望,免疫细胞死亡 (ICD) 影响瘤免疫微环境.
预测治疗预后的生物标志物对于指导LUAD治疗决策至关重要.

研究的目的:

在LUAD中识别新的免疫细胞死亡相关基因 (ICD-DEGs).
构建和验证基于ICD-DEGs的预后模型,用于预测LUAD患者的结果.
评估预后模型在引导LUAD患者免疫疗法选择中的潜力.

主要方法:

利用LUAD数据集来识别与ICD相关的差异表达基因 (DEG).
将DEGs分组成小组并进行差异分析.
建立并验证了使用LASSO Cox回归和生存分析的预后模型.

主要成果:

LUAD样本被分为两个子组,其中ICD高的子组表现出对免疫疗法敏感的免疫热表型.
使用六个与ICD相关的DEG开发了一个预后模型,证明高风险得分与更好的免疫治疗反应相关.
预后模型有效地预测了在LUAD中的ICD亚型和治疗预后.

结论:

开发的ICD预后模型是评估个别LUAD患者亚型的宝贵工具.
这种模型可以帮助预测治疗预后,并优化LUAD的免疫治疗策略.
识别与ICD相关的生物标志物有助于在LUAD治疗中推进个性化医学.

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.